Volume 11 Supplement 1

Challenges in malaria research

Open Access

Malaria elimination strategy and challenges in People’s Republic of China

  • Xiao-Nong Zhou1,
  • Shu-Shen Zhou1 and
  • Xia Zi-Guang1
Malaria Journal201211(Suppl 1):P138


Published: 9 November 2012


Malaria remains an infectious disease of foremost public health importance in the People’s Republic of China. Historically, high malaria incidence rates have been reported from 24 provinces of P.R. China with more than 30 million cases annually reported. With the significant reduction of malaria incidence, the national malaria elimination was launched in 2010.


The risk factors related to malaria transmission in China was reviewed based on the previous literature reviewing, and the capacity of malaria elimination was analysed based on the readiness in surveillance and response system. The challenges and future research priorities related to the elimination strategy were put forward.


Owing to large-scale control activities facilitated through primary healthcare networks and community participation, the infection rate of Plasmodium vivax has been reduced to under 0.01% in most areas of China, and P. falciparum malaria has been eliminated in most provinces, except Yunnan and Hainan. The elimination strategy formulation and its readiness analysis were performed with discussion on the challenges for the national malaria elimination programme in China, while the sourthern border areas in Yunnan will be the one of most hard issue to elimination the disease. Finally the recommendation on surveillance and response approaches based on currently satus leading to malaria elimination in China were put forward.


The national malaria elimination programme launched in 2010 is able to achieve its optimal goal to eliminate malaria in whole country by 2020, if facilitated by surveillance and response system.

Authors’ Affiliations

National Institute of Parasitic Diseases, China CDC


© Zhou et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.